Faculty Bibliography

OBJECTIVE. The objective of our study was to compare interreader reproducibility of the recently proposed "Prostate Imaging Reporting and Data System," or "PI-RADS," scale incorporating fixed criteria and a standard Likert scale based on overall impression for prostate cancer localization using multiparametric MRI. MATERIALS AND METHODS. Fifty-five patients who underwent a 3-T prostate MRI examination using a pelvic phased-array coil and incorporating T2-weighted imaging, diffusion-weighted imaging, and dynamic contrast-enhanced imaging were included in the study. Three radiologists (6, 4, and 1 year of experience) independently scored 18 regions (12 in the peripheral zone [PZ] and six in the transition zone [TZ]) using PI-RADS (range, 3-15) and Likert (range, 1-5) scales, which were based on fixed criteria and overall impression, respectively. Interreader reproducibility was evaluated using the concordance correlation coefficient (CCC), which assesses exact agreement between scores (minimal, < 0.2; poor, 0.2-<0.4; moderate, 0.4-<0.6; strong, 0.6-<0.8; almost perfect, >/= 0.8). RESULTS. Agreement between experienced readers was strong in the PZ and TZ combined and in the PZ for both the PI-RADS and Likert scales (CCC = 0.608-0.677), moderate in the TZ for the Likert scale (CCC = 0.519), and poor in the TZ for PI-RADS (CCC = 0.376). Agreement between experienced and inexperienced readers was moderate to poor in the PZ and TZ combined for PI-RADS (CCC = 0.340-0.477), moderate in the PZ and TZ combined for the Likert scale (CCC = 0.471-0.497), moderate in the PZ for PI-RADS and Likert scales (CCC = 0.472-0.542), minimal to poor in the TZ for PI-RADS (CCC = 0.094-0.283), and poor in the TZ for the Likert scale (CCC = 0.287-0.400). CONCLUSION. Interreader reproducibility tended to be higher for relatively experienced readers than for less experienced readers and to be higher in the PZ than in the TZ. For the relatively experienced readers, reproducibility was similar for PI-RADS and Likert scales in the PZ but was somewhat higher for the Likert scale than for PI-RADS in the TZ.

OBJECTIVE. The objective of this study was to compare the performance of different methodologies for interpretation of dynamic contrast-enhanced MRI (DCE-MRI) in localization of peripheral zone prostate cancer. MATERIALS AND METHODS. Forty-three men (mean age, 59 +/- 8 years) with biopsy-proven prostate cancer who underwent prostate MRI including DCE-MRI before prostatectomy were included. Two observers independently reviewed DCE-MRI data using three methodologies: qualitative, in which kinetic curves of signal intensity versus time were generated for foci showing rapid enhancement on subtracted contrast-enhanced images; semiquantitative, in which a biexponential heuristic model was used to generate color-coded maps depicting maximum slope and washout of contrast enhancement; and quantitative, in which a Tofts model was used to generate color-coded influx rate transfer constant (K(trans)) and efflux rate transfer constant (Kep) maps. Findings were stratified by whether suspicious foci showed evidence of washout with each method and compared with histopathologic results in each sextant. RESULTS. There was similar accuracy for the semiquantitative and quantitative models for both observers irrespective of requiring evidence of washout. For the more experienced observer, requiring washout resulted in lower sensitivity and higher specificity for the qualitative and semiquantitative models. Also for the more experienced observer, use of either a semiquantitative or quantitative model provided greater sensitivity compared with a qualitative model when requiring washout. There was no association between tumor detection and Gleason score for any DCE-MRI methodology for either reader. CONCLUSION. For the experienced reader, sensitivity for peripheral zone tumor was increased by use of either a semiquantitative or quantitative model compared with a qualitative model and decreased by requiring washout. We failed to identify a difference in performance between semiquantitative and quantitative models.

IMPORTANCE: Soy consumption has been suggested to reduce risk or recurrence of prostate cancer, but this has not been tested in a randomized trial with prostate cancer as the end point. OBJECTIVE: To determine whether daily consumption of a soy protein isolate supplement for 2 years reduces the rate of biochemical recurrence of prostate cancer after radical prostatectomy or delays such recurrence. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind trial conducted from July 1997 to May 2010 at 7 US centers comparing daily consumption of a soy protein supplement vs placebo in 177 men at high risk of recurrence after radical prostatectomy for prostate cancer. Supplement intervention was started within 4 months after surgery and continued for up to 2 years, with prostate-specific antigen (PSA) measurements made at 2-month intervals in the first year and every 3 months thereafter. INTERVENTION: Participants were randomized to receive a daily serving of a beverage powder containing 20 g of protein in the form of either soy protein isolate (n=87) or, as placebo, calcium caseinate (n=90). MAIN OUTCOMES AND MEASURES: Biochemical recurrence rate of prostate cancer (defined as development of a PSA level of >/=0.07 ng/mL) over the first 2 years following randomization and time to recurrence. RESULTS: The trial was stopped early for lack of treatment effects at a planned interim analysis with 81 evaluable participants in the intervention group and 78 in the placebo group. Overall, 28.3% of participants developed biochemical recurrence within 2 years of entering the trial (close to the a priori predicted recurrence rate of 30%). Among these, 22 (27.2%) occurred in the intervention group and 23 (29.5%) in the placebo group. The resulting hazard ratio for active treatment was 0.96 (95% CI, 0.53-1.72; log-rank P = .89). Adherence was greater than 90% and there were no apparent adverse events related to supplementation. CONCLUSION AND RELEVANCE: Daily consumption of a beverage powder supplement containing soy protein isolate for 2 years following radical prostatectomy did not reduce biochemical recurrence of prostate cancer in men at high risk of PSA failure. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00765479.